STOCK TITAN

Avita Medical Inc - RCEL STOCK NEWS

Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.

Avita Medical Inc (RCEL) delivers breakthrough regenerative medicine solutions through its FDA-approved RECELL system, transforming wound care and skin restoration. This news hub provides investors and medical professionals with essential updates on clinical advancements, regulatory milestones, and strategic initiatives.

Access authoritative information about RCEL's innovative approach to burn treatment and skin repair, including FDA clearances, international regulatory progress, and partnerships shaping the future of point-of-care cell therapy. Our curated collection features press releases on product innovations, peer-reviewed research validations, and market expansion activities.

Key content categories include clinical trial outcomes, regulatory submissions, financial performance updates, and technological refinements to the RECELL platform. Users benefit from centralized access to verified information supporting informed analysis of this medical device innovator.

Bookmark this page for streamlined tracking of Avita Medical's progress in advancing regenerative wound care solutions. Check regularly for updates demonstrating how RCEL's patented technology continues to redefine standards in acute burn treatment and complex wound management.

Rhea-AI Summary

AVITA Medical announced that the Biomedical Advanced Research and Development Authority (BARDA) has modified its contract to fund the ongoing pivotal clinical trial for the RECELL System aimed at soft tissue reconstruction.

The trial compares conventional autografting with RECELL in treating acute non-burn full-thickness skin defects, targeting fewer donor skin needs without compromising healing. BARDA’s support highlights the potential of RECELL in expanding treatment indications beyond burns, acknowledging its significance for patients suffering trauma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
none
-
Rhea-AI Summary

AVITA Medical announced a group purchasing agreement with Premier, Inc. that facilitates the access of approximately 4,440 U.S. hospitals to its RECELL System for treating severe burns. This agreement allows Premier members to utilize special pricing and terms, ensuring timely patient treatment. The RECELL System allows healthcare providers to produce a suspension of Spray-On Skin™ Cells from a small skin sample for effective burn treatment. CEO Dr. Mike Perry highlighted the importance of this agreement for improving patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
Rhea-AI Summary

AVITA Medical (NASDAQ: RCEL) reported strong financial results for the quarter ending December 31, 2021, with revenue increasing by 37% to $14.0 million. The fourth quarter saw a revenue growth of 35% to $6.9 million compared to the prior year. The company achieved significant milestones including FDA approval of the enhanced RECELL® system and completed enrollment for pivotal clinical trials aimed at soft tissue reconstruction and vitiligo. However, net losses widened by 52% to $8.5 million. Moving forward, AVITA projects a revenue of approximately $30 million in 2022, marking a 20% increase year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.89%
Tags
Rhea-AI Summary

AVITA Medical, Inc. (NASDAQ: RCEL) has received approval from Japan's Pharmaceuticals and Medical Devices Agency to market its RECELL® System for treating burns. This system significantly reduces the need for donor skin by preparing Spray-On Skin™ Cells from a small amount of the patient’s skin. With Japan being the second-largest healthcare market globally, this approval opens up opportunities for treating over 6,000 severe burn patients annually. COSMOTEC, part of M3 Group, is the distribution partner tasked with making the treatment widely available in Japanese medical institutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
partnership
-
Rhea-AI Summary

AVITA Medical, a regenerative medicine company, announced Dr. Mike Perry's presentation at the Cowen 42nd Annual Health Care Conference on March 8, 2022. The event will be accessible through the company website. AVITA specializes in technology for autologous skin restoration, addressing needs in burns and chronic wounds. Its RECELL System, FDA-approved since September 2018, utilizes a patient's skin cells to treat burns, minimizing donor skin requirements. It has shown to significantly improve clinical outcomes and cost savings, with over 10,000 patients treated worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
conferences
-
Rhea-AI Summary

AVITA Medical announced FDA approval for an enhanced version of its RECELL® Autologous Cell Harvesting Device, aimed at improving clinician efficiency in treating acute thermal burns. The new system simplifies workflows, reducing setup steps by one-third and requiring fewer support personnel. User surveys indicate 94% believe the device will speed up preparation, while over 80% expect a faster learning curve for new users. The product launch in the U.S. is slated for Q2 2022, reinforcing the company's commitment to advancing regenerative medicine solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
Rhea-AI Summary

AVITA Medical (NASDAQ: RCEL) announced plans to release its financial results for the second half of 2021 on February 28, 2022, after market close. A conference call will follow to discuss these results. The company switched to a calendar year reporting system starting January 1, 2022. AVITA Medical is focused on regenerative medicine and offers the RECELL® System for treating burns by using a patient’s own skin cells, enhancing healing while reducing the need for donor skin.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
-
Rhea-AI Summary

AVITA Medical, Inc. (NASDAQ: RCEL) announced that CEO Dr. Mike Perry will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 10:30 a.m. EST. The conference aims to showcase advancements in regenerative medicine, particularly AVITA's RECELL® System for treating acute thermal burns. This innovative technology uses a patient's own skin cells to regenerate healthy epidermis, significantly reducing the amount of donor skin needed. The RECELL System is FDA-approved and has demonstrated superior clinical outcomes in over 10,000 patients globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
conferences
-
Rhea-AI Summary

AVITA Medical has announced the acceptance of six abstracts at the 44th Annual John A. Boswick Burn & Wound Care Symposium, showcasing the clinical benefits of the RECELL® System for burn treatment. Held in Maui from January 22-27, these presentations highlight the system's advancements in treating burn wounds. With pivotal clinical trials for vitiligo and soft tissue reconstruction complete, the company aims to leverage its innovative technology for broader patient benefits. The RECELL® System has received significant recognition and is now used in over 10,000 patients worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
Rhea-AI Summary

AVITA Medical, Inc. (NASDAQ: RCEL) announced preliminary unaudited results for Q4 2021, reporting a 35% revenue increase to $6.9 million compared to $5.1 million in Q4 2020. As of December 31, 2021, the company held approximately $55.5 million in cash and marketable securities with no debt. The company completed enrollment in two pivotal clinical trials for its RECELL® System, aimed at treating vitiligo and soft tissue reconstruction, targeting FDA submissions in late 2022. Additionally, proof of concept was established in cell-based gene therapy for skin rejuvenation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
none
Avita Medical Inc

Nasdaq:RCEL

RCEL Rankings

RCEL Stock Data

242.75M
26.21M
0.82%
24.74%
6.55%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
VALENCIA